No. |
Variant name |
Chromosome position |
Chromatin state |
Related regulatory elements |
Target genes |
Extended variants |
Associated traits |
1 |
rs548107464 |
chr5:1927576-1927577 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
2 |
rs558205193 |
chr5:1927592-1927593 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
3 |
rs566254745 |
chr5:1927642-1927643 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
4 |
rs568081698 |
chr5:1927650-1927651 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
5 |
rs6555028 |
chr5:1927658-1927659 |
Enhancers Weak transcription
|
n/a
|
n/a
|
LD-proxies of rSNPOverlapped rCNV
|
n/a
|
6 |
rs368861418 |
chr5:1927667-1927668 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
7 |
rs554887967 |
chr5:1927675-1927676 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
8 |
rs576195522 |
chr5:1927708-1927709 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
9 |
rs190613928 |
chr5:1927741-1927742 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
10 |
rs373379521 |
chr5:1927772-1927773 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
11 |
rs557131170 |
chr5:1927799-1927800 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
12 |
rs183605818 |
chr5:1927823-1927824 |
Enhancers Weak transcription Bivalent Enhancer
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
13 |
rs575705222 |
chr5:1927827-1927828 |
Enhancers Weak transcription Bivalent Enhancer
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
14 |
rs368384604 |
chr5:1927828-1927829 |
Enhancers Weak transcription Bivalent Enhancer
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
15 |
rs541019967 |
chr5:1927843-1927844 |
Enhancers Weak transcription Bivalent Enhancer
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
16 |
rs559651159 |
chr5:1927865-1927866 |
Enhancers Weak transcription Bivalent Enhancer
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
17 |
rs572270752 |
chr5:1927875-1927876 |
Enhancers Weak transcription Bivalent Enhancer
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
18 |
rs542870905 |
chr5:1927898-1927899 |
Enhancers Weak transcription Bivalent Enhancer
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
19 |
rs536848645 |
chr5:1927955-1927956 |
Enhancers Weak transcription Bivalent Enhancer
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
20 |
rs375379869 |
chr5:1927956-1927957 |
Enhancers Weak transcription Bivalent Enhancer
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
21 |
rs560956465 |
chr5:1927969-1927970 |
Enhancers Weak transcription Bivalent Enhancer
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
22 |
rs558741308 |
chr5:1927970-1927971 |
Enhancers Weak transcription Bivalent Enhancer
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
23 |
rs531511233 |
chr5:1927978-1927979 |
Enhancers Weak transcription Bivalent Enhancer
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
24 |
rs9885094 |
chr5:1927979-1927980 |
Enhancers Weak transcription Bivalent Enhancer
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
25 |
rs577193174 |
chr5:1927981-1927982 |
Enhancers Weak transcription Bivalent Enhancer
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
26 |
rs372281639 |
chr5:1927995-1927996 |
Enhancers Weak transcription Bivalent Enhancer
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
27 |
rs4285271 |
chr5:1928013-1928014 |
Flanking Active TSS Enhancers Flanking Bivalent TSS/Enh Weak transcription Bivalent Enhancer
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
28 |
rs146676254 |
chr5:1928036-1928037 |
Flanking Active TSS Enhancers Flanking Bivalent TSS/Enh Weak transcription Bivalent Enhancer
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
29 |
rs559704844 |
chr5:1928043-1928044 |
Flanking Active TSS Enhancers Flanking Bivalent TSS/Enh Weak transcription Bivalent Enhancer
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
30 |
rs574436743 |
chr5:1928048-1928049 |
Flanking Active TSS Enhancers Flanking Bivalent TSS/Enh Weak transcription Bivalent Enhancer
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
31 |
rs564962195 |
chr5:1928072-1928073 |
Flanking Active TSS Enhancers Flanking Bivalent TSS/Enh Weak transcription Bivalent Enhancer
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
32 |
rs532202907 |
chr5:1928076-1928077 |
Flanking Active TSS Enhancers Flanking Bivalent TSS/Enh Weak transcription Bivalent Enhancer
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
33 |
rs140173577 |
chr5:1928083-1928084 |
Flanking Active TSS Enhancers Flanking Bivalent TSS/Enh Weak transcription Bivalent Enhancer
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
34 |
rs186405504 |
chr5:1928143-1928144 |
Flanking Active TSS Enhancers Flanking Bivalent TSS/Enh Weak transcription Bivalent Enhancer
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
35 |
rs536560176 |
chr5:1928156-1928157 |
Flanking Active TSS Enhancers Flanking Bivalent TSS/Enh Weak transcription Bivalent Enhancer
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
36 |
rs548850855 |
chr5:1928163-1928164 |
Flanking Active TSS Enhancers Flanking Bivalent TSS/Enh Weak transcription Bivalent Enhancer
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
37 |
rs369440228 |
chr5:1928187-1928188 |
Flanking Active TSS Enhancers Flanking Bivalent TSS/Enh Weak transcription Bivalent Enhancer
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
38 |
rs569946742 |
chr5:1928194-1928195 |
Flanking Active TSS Enhancers Flanking Bivalent TSS/Enh Weak transcription Bivalent Enhancer
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
39 |
rs56099636 |
chr5:1928254-1928255 |
Flanking Active TSS Enhancers Weak transcription Bivalent Enhancer
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
40 |
rs199978162 |
chr5:1928257-1928258 |
Flanking Active TSS Enhancers Weak transcription Bivalent Enhancer
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
41 |
rs558669412 |
chr5:1928258-1928259 |
Flanking Active TSS Enhancers Weak transcription Bivalent Enhancer
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
42 |
rs541818785 |
chr5:1928266-1928267 |
Flanking Active TSS Enhancers Weak transcription Bivalent Enhancer
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
43 |
rs191314018 |
chr5:1928353-1928354 |
Flanking Active TSS Enhancers Weak transcription Bivalent Enhancer
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
44 |
rs182609156 |
chr5:1928354-1928355 |
Flanking Active TSS Enhancers Weak transcription Bivalent Enhancer
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
45 |
rs188028043 |
chr5:1928393-1928394 |
Flanking Active TSS Enhancers Weak transcription Bivalent Enhancer
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
46 |
rs191409518 |
chr5:1928448-1928449 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
47 |
rs183500250 |
chr5:1928460-1928461 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
48 |
rs563226408 |
chr5:1928470-1928471 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
49 |
rs542583392 |
chr5:1928493-1928494 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
50 |
rs559880356 |
chr5:1928512-1928513 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|